MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-1006 in Japanese Subject With Type 2 Diabetes

A single rising dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM). The primary hypothesis of the study is that single doses of MK-1006 will be sufficiently safe and well tolerated, based on the assessment of clinical and laboratory evaluations and adverse experiences, in Japanese participants with T2DM.

Inclusion Criteria:

• Japanese male or female between 20 to 64 years of age
• Diagnosis of type 2 diabetes
• Patient is being treated with diet and exercise alone or single oral anti-hyperglycemic agent

Exclusion Criteria:

• Subject has a history of type 1 diabetes mellitus
• Subject has a clinical diagnosis of glaucoma
• Subject has donated blood or participated in another clinical study in the past 12 weeks
• Subject is a regular user of any illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months